CRVO earnings: next report 2026-08-14, real EPS beat/miss history, analyst consensus Buy, P/E -0.85. Updated 2026-07-23.
CervoMed (CRVO) Research Hub
CervoMed (CRVO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.57 USD (+2.39%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.85, market cap 0.03B. This hub links to the full technical, earnings and options research available for CRVO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.57 USD (+2.39%) |
| 52-week range | 2.42 USD – 4.46 USD |
| Trend regime | Range |
| 14-day RSI | 37.1 (Bearish) |
| Trailing P/E | -0.85 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for CRVO
Covered Call on CRVO: how it works, illustrative setup around the real 2.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRVO: how it works, illustrative setup around the real 2.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRVO: how it works, illustrative setup around the real 2.57 USD price, max profit/loss, breakeven and when to use it. Educational.
CRVO technical analysis: range, last 2.57 USD, RSI 37.1, 52w range 2.42 USD–4.46 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CRVO in?
CervoMed (CRVO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CRVO in an uptrend or downtrend?
As of 2026-09-11, CRVO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRVO's trailing P/E ratio?
CRVO's trailing P/E is -0.85, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does CRVO next report earnings?
CRVO is next scheduled to report earnings on 2026-08-14, with a consensus EPS estimate of -0.79857 USD.